Table 2.
Groups | GSH (μmol/g) | MDA (mmol/ml) | SOD (U/mg) |
---|---|---|---|
Control | 7.733 ± 0.777 | 4.473 ± 0.302 | 14.621 ± 0.494 |
ISP | 1.600 ± 0.267∗ | 10.131 ± 0.468∗ | 7.887 ± 0.599∗ |
CFME-LD per se | 6.933 ± 0.499 | 3.940 ± 0.179 | 14.321 ± 0.315 |
CFME-HD per se | 6.933 ± 0.499 | 3.740 ± 0.549 | 15.431 ± 0.249 |
CFME-LD + ISP | 4.267 ± 0.499∗∗∗ | 7.460 ± 0.411∗∗∗ | 10.431 ± 0.631∗∗∗ |
CFME-HD + ISP | 4.533 ± 0.533∗∗ | 7.753 ± 0.684∗∗ | 11.021 ± 0.464∗∗ |
ISP: Isoproterenol; CFME-LD: CFME at lower dose (250 mg/kg); CFME-HD: CFME at higher dose (500 mg/kg). Data are expressed as mean value ± S.E.M (n = 7) analyzed using one-way ANOVA followed by Tukey's multiple comparison test. ∗p < 0.001 when compared to the control group, ∗∗∗p < 0.05, ∗∗p < 0.01 when compared to the ISP control group.